Eva Poveda López-rekin lankidetzan egindako argitalpenak (23)

2017

  1. Human T-lymphotropic virus type 1 infection and disease in Spain

    AIDS, Vol. 31, Núm. 12, pp. 1653-1663

2015

  1. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  2. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2012

  1. Pharmacogenetics of hepatitis C

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 3, pp. 523-529

  2. Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain

    Antiviral Therapy, Vol. 17, Núm. 3, pp. 571-575

  3. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor

    Antiviral Therapy, Vol. 17, Núm. 5, pp. 921-926

  4. Treatment failure with new hepatitis C drugs

    Expert Opinion on Pharmacotherapy, Vol. 13, Núm. 3, pp. 313-323

2011

  1. Directly acting antivirals against hepatitis C virus

    Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 8, pp. 1673-1686

2009

  1. Raltegravir and etravirine are active against HIV Type 1 group O

    AIDS Research and Human Retroviruses, Vol. 25, Núm. 2, pp. 225-227